biostudies-literatureUnknown54Mao SHeart failure resulting from myocardial infarction (MI) is a leading global health concern. Current revascularization therapies cannot fully restore the infarcted myocardium or prevent maladaptive ventricular remodeling. Traditional Chinese medicine with its multitarget regulation and favorable biosafety shows a promising therapeutic potential. Tanshinone IIA (TIIA) and formononetin (FM), two bioactive compounds derived from <i>Salvia miltiorrhiza</i> and <i>Astragalus membranaceus</i>, respectively, exhibit antioxidant, anti-inflammatory, and proangiogenic effects. Herein, a neutrophil-targeted nanomedicine (TF-5NP) was developed to deliver TIIA and FM to the infarcted myocardium for mitigating oxidative damage and promoting angiogenesis. TF-5NP was synthesized by coassembling <i>bis</i>-Bioactive materials648-665https://www.ebi.ac.uk/biostudies/studies/S-EPMC12451291biostudies-literatureAdaptive bioactivable nanosystems for synergistic myocardial infarction therapy using traditional pharmaceutics.PMC12451291Chen QYu LFang ZMao SChen ZLiang YZhang HZheng QYu ZWang LMa WfalseAdaptive bioactivable nanosystems for synergistic myocardial infarction therapy using traditional pharmaceutics.Heart failure resulting from myocardial infarction (MI) is a leading global health concern. Current revascularization therapies cannot fully restore the infarcted myocardium or prevent maladaptive ventricular remodeling. Traditional Chinese medicine with its multitarget regulation and favorable biosafety shows a promising therapeutic potential. Tanshinone IIA (TIIA) and formononetin (FM), two bioactive compounds derived from <i>Salvia miltiorrhiza</i> and <i>Astragalus membranaceus</i>, respectively, exhibit antioxidant, anti-inflammatory, and proangiogenic effects. Herein, a neutrophil-targeted nanomedicine (TF-5NP) was developed to deliver TIIA and FM to the infarcted myocardium for mitigating oxidative damage and promoting angiogenesis. TF-5NP was synthesized by coassembling <i>bis</i>-2025-01-01T00:00:00Z2025 Dec2026-06-03T19:14:16.142Z2026-05-30T03:06:40.826ZS-EPMC124512914098894010.1016/j.bioactmat.2025.08.041